SLC5A2 and type 2 diabetes mellitus: The use of SGLT2 inhibitors is now recommended as part of treatment protocols based on international guidelines, including the Kidney Disease: Improving Global Outcomes (KDIGO) 2022, which advise their administration for patients with T2DM and CKD, regardless of glycemic control [26].